|
|
viii | |
Preface |
|
ix | |
|
|
|
|
1 | (10) |
|
|
Pivotal Cases for Software IP Protection |
|
|
1 | (3) |
|
Turning Points for Biotech IP Policy |
|
|
4 | (1) |
|
|
5 | (3) |
|
|
8 | (3) |
|
An Overview of the Economics of Intellectual Property Protection |
|
|
11 | (34) |
|
|
|
13 | (7) |
|
Some Classical Theory: Information Property Rights Increase Innovation |
|
|
13 | (4) |
|
Some Recent Theory: Strong Patents Can Erect Barriers |
|
|
17 | (3) |
|
The Empirical IPR Literature |
|
|
20 | (17) |
|
Do Strong Patents Spur Innovation? |
|
|
20 | (4) |
|
Do Patents Increase Information Disclosure? |
|
|
24 | (2) |
|
Do Patents Increase Technology Transfer? |
|
|
26 | (3) |
|
Do Patents Increase Commercial Development? |
|
|
29 | (2) |
|
Do Patents Increase Economic Development? |
|
|
31 | (4) |
|
The Crucial Role of Data and Measurement |
|
|
35 | (2) |
|
|
37 | (2) |
|
|
39 | (6) |
|
Software Patents: Good News or Bad News? |
|
|
45 | (36) |
|
|
|
|
46 | (3) |
|
The Historical Development of the Computer Software Industry |
|
|
49 | (3) |
|
The Evolution of Intellectual Property Rights Policy and Practice in the U.S. Software Industry |
|
|
52 | (4) |
|
|
52 | (1) |
|
|
53 | (3) |
|
Patenting Trends in the U.S. Software Industry, 1987--2003 |
|
|
56 | (13) |
|
Software-Related Patenting by Packaged Software and Electronic Systems Firms, 1987--2003 |
|
|
62 | (3) |
|
Changes in the ``Patent Propensity'' of Packaged-Software Firms, 1987--2003 |
|
|
65 | (4) |
|
|
69 | (4) |
|
|
73 | (3) |
|
|
76 | (5) |
|
Designing Optimal Software Patents |
|
|
81 | (28) |
|
|
|
|
82 | (7) |
|
|
82 | (2) |
|
|
84 | (2) |
|
|
86 | (3) |
|
|
89 | (2) |
|
|
91 | (4) |
|
|
95 | (5) |
|
|
96 | (2) |
|
|
98 | (1) |
|
|
99 | (1) |
|
|
100 | (1) |
|
|
101 | (8) |
|
State Street Meets the Human Genome Project: Intellectual Property and Bioinformatics |
|
|
109 | (22) |
|
|
Patenting Activity in Bioinformatics |
|
|
111 | (1) |
|
Gene Patent Issues Revisited? |
|
|
112 | (2) |
|
Implications of State Street |
|
|
114 | (1) |
|
Challenges Posed by a Frontier Technology |
|
|
115 | (2) |
|
|
117 | (2) |
|
|
119 | (2) |
|
|
121 | (3) |
|
|
124 | (2) |
|
|
126 | (5) |
|
``Open and Collaborative'' Research: A New Model for Biomedicine |
|
|
131 | (28) |
|
|
The Open and Collaborative Model in Context |
|
|
134 | (2) |
|
Innovation in Biopharmaceuticals |
|
|
134 | (1) |
|
Vertical ``Dis-Integration'' and Calls for Access |
|
|
135 | (1) |
|
Beyond Access: Open and Collaborative Research |
|
|
136 | (9) |
|
|
137 | (3) |
|
Open and Collaborative Biomedical Research |
|
|
140 | (5) |
|
Open and Collaborative Biomedical Research: A Critical Evaluation |
|
|
145 | (6) |
|
Open Source Bioinformatics Software |
|
|
145 | (2) |
|
Open and Collaborative Databases |
|
|
147 | (1) |
|
|
148 | (3) |
|
|
151 | (2) |
|
|
153 | (6) |
|
Does Open Source Have Legs? |
|
|
159 | (18) |
|
|
|
159 | (3) |
|
Open Source and the Tradeoffs Associated with R & D Information Flows |
|
|
162 | (2) |
|
|
164 | (2) |
|
Can Open Source Methods Be Applied to Biomedical Research? |
|
|
166 | (2) |
|
Should Open Source Methods Be Applied to Biomedicine? |
|
|
168 | (2) |
|
|
170 | (1) |
|
|
171 | (2) |
|
|
173 | (4) |
Index |
|
177 | (8) |
About the Authors |
|
185 | |